FDA Approved: FASENRA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for FASENRA (benralizumab) from AstraZeneca, updating its labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

SUPPL AP for FASENRA (BENRALIZUMAB)